Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-21-5p ABAT 1.51 0 -2.16 0 MirTarget -0.93 0 NA
2 hsa-miR-21-5p ABCA1 1.51 0 -1.1 0 mirMAP -0.29 0 NA
3 hsa-miR-21-5p ABCA10 1.51 0 -1.06 4.0E-5 mirMAP -0.45 0 NA
4 hsa-miR-21-5p ABCD3 1.51 0 -0.9 0 miRNAWalker2 validate -0.38 0 NA
5 hsa-miR-21-3p ACAD11 -0.48 0.003 -1.86 0 MirTarget -0.24 1.0E-5 NA
6 hsa-miR-21-5p ACAT1 1.51 0 -1.62 0 miRNAWalker2 validate -0.62 0 NA
7 hsa-miR-21-5p ACBD5 1.51 0 -0.75 0 miRNAWalker2 validate; miRNATAP -0.33 0 NA
8 hsa-miR-21-5p ACVR2A 1.51 0 -0.55 0 miRNATAP -0.17 0 NA
9 hsa-miR-21-5p AIM1 1.51 0 -1.46 0 miRNAWalker2 validate -0.35 0 NA
10 hsa-miR-21-5p AKAP6 1.51 0 -0.97 0 MirTarget -0.54 0 NA
11 hsa-miR-21-5p AKAP9 1.51 0 -0.79 0 miRNAWalker2 validate -0.29 0 NA
12 hsa-miR-21-5p AKIRIN1 1.51 0 -0.73 0 miRNATAP -0.13 0.00038 NA
13 hsa-miR-21-5p AKT2 1.51 0 -0.34 1.0E-5 miRNAWalker2 validate -0.25 0 NA
14 hsa-miR-221-3p AMOT 1.12 0 -0.9 0.00079 miRNAWalker2 validate -0.32 9.0E-5 NA
15 hsa-miR-21-5p ANKRD28 1.51 0 -0.36 1.0E-5 miRNAWalker2 validate -0.17 0 NA
16 hsa-miR-21-5p ANKRD46 1.51 0 -0.78 0 miRNAWalker2 validate; miRTarBase -0.41 0 21219636 Knockdown of miR-21 significantly increased the expression of ANKRD46 at both mRNA and protein levels; ANKRD46 is newly identified as a direct target of miR-21 in BC
17 hsa-miR-21-5p ANO3 1.51 0 -2.3 0 mirMAP -0.98 0 NA
18 hsa-miR-21-5p AP1AR 1.51 0 -0.61 0 MirTarget; miRNATAP -0.25 0 NA
19 hsa-miR-21-5p APC 1.51 0 -0.18 0.06792 miRNAWalker2 validate -0.17 0 23773491; 24832083 The prognostic significance of APC gene mutation and miR 21 expression in advanced stage colorectal cancer; The aim of this study was to analyse the association of APC gene mutation and miR-21 expression with clinical outcome in CRC patients; APC gene mutation and expression of APC and miR-21 were analysed by direct DNA sequencing and real-time reverse transcription polymerase chain reaction; APC gene expression was low in CRC and negatively correlated with miR-21 expression and gene mutation; In Taiwan downregulation of the APC gene in CRC correlated with gene mutation and miR-21 upregulation; APC mutation and miR-21 expression could be used to predict the clinical outcome of CRC especially in patients with advanced disease;MicroRNA 21 promotes tumour malignancy via increased nuclear translocation of β catenin and predicts poor outcome in APC mutated but not in APC wild type colorectal cancer; However in our preliminary data the prognostic value of miR-21 levels was observed only in adenomatous polyposis coli APC-mutated tumours not in APC-wild-type tumours; We enrolled 165 colorectal tumour to determine APC mutation miR-21 levels and nuclear β-catenin expression by direct sequencing real-time PCR and immunohistochemistry
20 hsa-miR-21-5p APOLD1 1.51 0 0.45 0.00929 miRNAWalker2 validate -0.18 0.00545 NA
21 hsa-miR-221-3p AQP3 1.12 0 -1.9 0 MirTarget -0.17 0.00795 NA
22 hsa-miR-221-3p ARAP2 1.12 0 -1.13 0 MirTarget -0.14 0.00818 NA
23 hsa-miR-21-5p ARHGAP21 1.51 0 -0.09 0.37274 miRNAWalker2 validate -0.11 0.00286 NA
24 hsa-miR-21-5p ARHGAP24 1.51 0 -0.99 0 MirTarget; miRNATAP -0.36 0 NA
25 hsa-miR-21-5p ARHGAP32 1.51 0 -0.2 0.09921 MirTarget -0.29 0 NA
26 hsa-miR-221-3p ARHGAP42 1.12 0 -1.24 0 miRNAWalker2 validate; MirTarget; miRNATAP -0.4 0 NA
27 hsa-miR-21-5p ARHGEF12 1.51 0 -0.86 0 miRNAWalker2 validate; MirTarget -0.26 0 NA
28 hsa-miR-21-5p ARID4A 1.51 0 -0.9 0 miRNAWalker2 validate -0.43 0 NA
29 hsa-miR-21-3p ARMC5 -0.48 0.003 -0.65 1.0E-5 mirMAP -0.11 0.01109 NA
30 hsa-miR-21-5p ART4 1.51 0 -1.74 0 mirMAP -0.48 1.0E-5 NA
31 hsa-miR-21-3p ASB4 -0.48 0.003 -0.62 0.06683 MirTarget -0.46 0 NA
32 hsa-miR-221-3p ASB4 1.12 0 -0.62 0.06683 MirTarget -0.34 0.00111 NA
33 hsa-miR-221-3p ASB7 1.12 0 -0.2 0.00927 miRNATAP -0.1 1.0E-5 NA
34 hsa-miR-221-3p ASPA 1.12 0 -2.88 0 MirTarget -0.66 0 NA
35 hsa-miR-21-5p ASPN 1.51 0 -1.64 0 MirTarget; miRNATAP -0.2 0.04902 NA
36 hsa-miR-221-3p ASXL3 1.12 0 -2.69 0 miRNAWalker2 validate -0.95 0 NA
37 hsa-miR-21-5p ATAD2B 1.51 0 -0.06 0.4791 miRNAWalker2 validate -0.14 3.0E-5 NA
38 hsa-miR-21-5p ATF2 1.51 0 -0.24 0.15619 miRNAWalker2 validate -0.18 0.00336 NA
39 hsa-miR-221-3p ATL2 1.12 0 -0.1 0.23951 miRNAWalker2 validate -0.1 5.0E-5 NA
40 hsa-miR-21-5p ATMIN 1.51 0 -0.37 0 miRNAWalker2 validate -0.12 0 NA
41 hsa-miR-21-5p ATP11B 1.51 0 -0.35 0.00133 miRNAWalker2 validate -0.16 4.0E-5 NA
42 hsa-miR-21-5p ATP2B2 1.51 0 -0.4 0.15518 mirMAP -0.24 0.01837 NA
43 hsa-miR-21-5p ATRN 1.51 0 0.12 0.34173 miRNATAP -0.17 0.00015 NA
44 hsa-miR-21-5p ATRNL1 1.51 0 -2.28 0 MirTarget -0.65 8.0E-5 NA
45 hsa-miR-21-5p ATRX 1.51 0 -0.07 0.48759 miRNAWalker2 validate -0.1 0.00335 NA
46 hsa-miR-21-5p ATXN3 1.51 0 -0.29 0.00037 mirMAP -0.22 0 NA
47 hsa-miR-21-5p AUTS2 1.51 0 -1.2 0 miRNAWalker2 validate -0.85 0 NA
48 hsa-miR-21-3p B4GALT6 -0.48 0.003 0.17 0.2792 MirTarget -0.11 0.02483 NA
49 hsa-miR-21-3p BACE1 -0.48 0.003 -0.45 0 mirMAP -0.16 0 NA
50 hsa-miR-21-5p BACE1 1.51 0 -0.45 0 mirMAP -0.29 0 NA
51 hsa-miR-21-5p BCL6 1.51 0 -0.38 0.00305 miRNAWalker2 validate -0.19 6.0E-5 NA
52 hsa-miR-21-5p BDH2 1.51 0 -1.59 0 miRNAWalker2 validate -0.57 0 NA
53 hsa-miR-21-5p BMP2K 1.51 0 -0.82 0 mirMAP -0.12 0.00963 NA
54 hsa-miR-21-5p BMPR2 1.51 0 -0.74 0 miRNAWalker2 validate; miRTarBase; MirTarget -0.28 0 NA
55 hsa-miR-221-3p BNIP3 1.12 0 -0.57 1.0E-5 miRNAWalker2 validate -0.19 0 NA
56 hsa-miR-221-3p BNIP3L 1.12 0 -0.67 0 miRNAWalker2 validate; miRTarBase -0.12 0.00023 NA
57 hsa-miR-21-5p BRD1 1.51 0 -0.22 0.01173 MirTarget -0.1 0.0018 NA
58 hsa-miR-221-3p BRWD1 1.12 0 -0.47 0 MirTarget -0.14 0 NA
59 hsa-miR-21-5p C16orf52 1.51 0 -0.5 0 miRNATAP -0.29 0 NA
60 hsa-miR-21-5p C1orf226 1.51 0 0.29 0.07217 mirMAP -0.13 0.03584 NA
61 hsa-miR-21-3p C22orf29 -0.48 0.003 1.09 0 mirMAP -0.11 0.00037 NA
62 hsa-miR-21-5p CADM2 1.51 0 -2.32 0 mirMAP; miRNATAP -0.38 0.00648 NA
63 hsa-miR-21-5p CALD1 1.51 0 -0.53 0 miRNAWalker2 validate; MirTarget -0.27 0 NA
64 hsa-miR-21-3p CAMK2A -0.48 0.003 -0.33 0.35691 MirTarget -0.43 5.0E-5 NA
65 hsa-miR-21-3p CAMLG -0.48 0.003 0.42 0 MirTarget -0.1 5.0E-5 NA
66 hsa-miR-221-3p CAMTA1 1.12 0 -0.31 0.0011 MirTarget -0.13 1.0E-5 NA
67 hsa-miR-21-5p CASC4 1.51 0 -0.46 0 miRNATAP -0.14 8.0E-5 NA
68 hsa-miR-221-3p CASR 1.12 0 -3.09 0 MirTarget -0.39 0.00241 NA
69 hsa-miR-221-3p CBWD3 1.12 0 -0.68 0 MirTarget -0.16 0.00013 NA
70 hsa-miR-21-3p CCDC117 -0.48 0.003 0.13 0.17161 MirTarget -0.19 0 NA
71 hsa-miR-21-5p CCDC121 1.51 0 0.09 0.43018 MirTarget -0.21 0 NA
72 hsa-miR-21-5p CCDC152 1.51 0 -1.09 0 mirMAP -0.61 0 NA
73 hsa-miR-21-3p CCDC158 -0.48 0.003 -1.41 0 MirTarget -0.19 0.01586 NA
74 hsa-miR-21-5p CCNG1 1.51 0 -0.05 0.64033 miRNAWalker2 validate -0.13 0.00024 NA
75 hsa-miR-221-3p CD4 1.12 0 -2.2 0 MirTarget; miRNATAP -0.35 0 NA
76 hsa-miR-21-3p CDADC1 -0.48 0.003 -0.68 0 MirTarget -0.22 0 NA
77 hsa-miR-21-3p CDC14B -0.48 0.003 -1.19 0 mirMAP -0.3 0 NA
78 hsa-miR-21-3p CDK14 -0.48 0.003 -0.02 0.85877 MirTarget -0.15 0.00044 NA
79 hsa-miR-221-3p CDKN1B 1.12 0 -0.23 0.00482 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.15 0 20146005; 23637992; 19953484; 23939688; 19126397; 23967190; 17569667; 22992757; 17721077; 20461750 Matched HCC and adjacent non-cancerous samples were assayed for the expression of miR-221 and three G1/S transition inhibitors: p27Kip1 p21WAF1/Cip1and TGF-β1 by in situ hybridization and immunohistochemistry respectively; Real time qRT-PCR was used to investigate miR-221 and p27Kip1 transcripts in different clinical stages; In result miR-221 and TGF-β1 are frequently up-regulated in HCC while p27Kip1 and p21WAF1/Cip1 proteins are frequently down-regulated; In conclusion miR-221 is important in tumorigenesis of HCC possibly by specifically down-regulating p27Kip1 a cell-cycle inhibitor;miR-221 knockdown not only blocked cell cycle progression induced cell apoptosis and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27kip1;Based on bioinformatic analysis we found that the seed sequences of miR-221 and miR-222 coincide with each other and p27kip1 is a target for miRNA-221/222;A Slug/miR-221 network has been suggested linking miR-221 activity with the downregulation of a Slug repressor leading to Slug/miR-221 upregulation and p27Kip1 downregulation; Interference with this process can be achieved using antisense miRNA antagomiR molecules targeting miR-221 inducing the downregulation of Slug and the upregulation of p27Kip1;Moreover a series of functional assays demonstrated that mir-221 could directly inhibit cKit p27Kip1 and possibly other pivotal proteins in melanoma;Additionally the PDGF-dependent increase in cell proliferation appears to be mediated by inhibition of a specific target of miR-221 and down-regulation of p27Kip1;miR 221 and miR 222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1; In all cell lines tested we show an inverse relationship between the expression of miR-221 and miR-222 and the cell cycle inhibitor p27Kip1; Consistently miR-221 and miR-222 knock-down through antisense LNA oligonucleotides increases p27Kip1 in PC3 cells and strongly reduces their clonogenicity in vitro;Peptide nucleic acids targeting miR 221 modulate p27Kip1 expression in breast cancer MDA MB 231 cells; Targeting miR-221 by PNA resulted in i lowering of the hybridization levels of miR-221 measured by RT-qPCR ii upregulation of p27Kip1 gene expression measured by RT-qPCR and western blot analysis;Antagonism of either microRNA 221 or 222 in glioblastoma cells also caused an increase in p27Kip1 levels and enhanced expression of the luciferase reporter gene fused to the p27Kip1 3'UTR;MiR 221 and MiR 222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B CDKNIC and overall survival; miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; In contrast CDKN1B expression was not associated with miR-221 or miR-222 expression
80 hsa-miR-21-3p CELF1 -0.48 0.003 -0.38 2.0E-5 MirTarget -0.11 6.0E-5 NA
81 hsa-miR-21-5p CLCN5 1.51 0 -0.78 0 miRNAWalker2 validate; mirMAP -0.33 0 NA
82 hsa-miR-221-3p CLN8 1.12 0 -0.9 0 mirMAP -0.14 0.00057 NA
83 hsa-miR-21-5p CLOCK 1.51 0 -0.53 0.00745 miRNAWalker2 validate -0.26 0.00029 NA
84 hsa-miR-21-3p CLYBL -0.48 0.003 -1.25 0 mirMAP -0.14 0.00887 NA
85 hsa-miR-221-3p CNRIP1 1.12 0 -0.55 3.0E-5 miRNAWalker2 validate -0.12 0.0033 NA
86 hsa-miR-21-5p CNTFR 1.51 0 -3.51 0 miRNATAP -1.1 0 NA
87 hsa-miR-21-3p COBL -0.48 0.003 -0.63 0.00023 MirTarget -0.14 0.0052 NA
88 hsa-miR-21-3p COBLL1 -0.48 0.003 -1.47 0 mirMAP -0.39 0 NA
89 hsa-miR-21-5p COBLL1 1.51 0 -1.47 0 miRNAWalker2 validate -0.8 0 NA
90 hsa-miR-21-5p CPEB3 1.51 0 -2.74 0 miRNAWalker2 validate; MirTarget; miRNATAP -0.98 0 NA
91 hsa-miR-221-3p CPNE8 1.12 0 -0.76 0 MirTarget; miRNATAP -0.3 0 NA
92 hsa-miR-21-5p CREBL2 1.51 0 -0.86 0 miRNATAP -0.28 0 NA
93 hsa-miR-221-3p CREBL2 1.12 0 -0.86 0 MirTarget -0.26 0 NA
94 hsa-miR-21-5p CRIM1 1.51 0 -0.43 0.03963 miRNATAP -0.15 0.04655 NA
95 hsa-miR-21-3p CRLS1 -0.48 0.003 -0.22 0.0807 MirTarget -0.27 0 NA
96 hsa-miR-21-5p CSNK1A1 1.51 0 -0.34 0 miRNAWalker2 validate -0.1 0 NA
97 hsa-miR-21-3p CTNNA3 -0.48 0.003 -2.94 0 MirTarget -0.41 8.0E-5 NA
98 hsa-miR-221-3p CXCL12 1.12 0 -3.59 0 MirTarget -0.31 0.00118 NA
99 hsa-miR-21-5p CYBRD1 1.51 0 -1.29 0 miRNAWalker2 validate -0.31 6.0E-5 NA
100 hsa-miR-221-3p CYP1B1 1.12 0 -0.08 0.76097 miRNAWalker2 validate; MirTarget -0.24 0.00202 NA
101 hsa-miR-21-3p CYP4F3 -0.48 0.003 -1.55 0 mirMAP -0.29 0.00125 NA
102 hsa-miR-21-5p CYP4V2 1.51 0 -1.71 0 miRNAWalker2 validate -0.71 0 NA
103 hsa-miR-21-5p DAAM1 1.51 0 -0.82 3.0E-5 miRNAWalker2 validate -0.58 0 NA
104 hsa-miR-21-5p DCAF10 1.51 0 -0.27 0.00016 miRNAWalker2 validate -0.19 0 NA
105 hsa-miR-21-5p DCAF8 1.51 0 -0.03 0.75166 miRNAWalker2 validate -0.16 0 NA
106 hsa-miR-221-3p DCUN1D1 1.12 0 -0.45 3.0E-5 MirTarget -0.18 0 NA
107 hsa-miR-21-3p DCUN1D4 -0.48 0.003 -0.24 0.00352 MirTarget -0.12 0 NA
108 hsa-miR-221-3p DCUN1D4 1.12 0 -0.24 0.00352 MirTarget -0.1 7.0E-5 NA
109 hsa-miR-21-5p DDAH1 1.51 0 -0.92 0 miRNAWalker2 validate -0.39 0 26741162 In vitro study showed QTsome/AM-21 induced upregulation of miR-21 targets including PTEN and DDAH1 in A549 cells while increasing their sensitivity toward paclitaxel PTX
110 hsa-miR-221-3p DDAH1 1.12 0 -0.92 0 miRNAWalker2 validate -0.23 0 NA
111 hsa-miR-21-3p DDI2 -0.48 0.003 -1.53 0 mirMAP -0.27 0.00598 NA
112 hsa-miR-21-5p DDR2 1.51 0 -0.84 0.00128 miRNAWalker2 validate -0.3 0.00149 NA
113 hsa-miR-21-5p DDX3X 1.51 0 -0.7 0 miRNAWalker2 validate -0.2 0 NA
114 hsa-miR-221-3p DDX3X 1.12 0 -0.7 0 miRNATAP -0.1 0.0001 NA
115 hsa-miR-221-3p DGKE 1.12 0 -0.86 0 miRNATAP -0.36 0 NA
116 hsa-miR-221-3p DIRAS3 1.12 0 -4.17 0 miRTarBase -0.99 0 21071579; 23801152; 22117988 Further studies on a new mechanism of ARHI downregulation showed a significant inverse relationship between ARHI and miR-221 and 222 which were upregulated in prostate cancer cell lines; Transfection of miR-221 and 222 inhibitors into PC-3 cells caused a significant induction of ARHI expression; A direct interaction of miR-221 or 222 with a target site on the 3'UTR of ARHI was confirmed by a dual luciferase pMIR-REPORT assay; Finally we also found that genistein upregulates ARHI by downregulating miR-221 and 222 in PC-3 cells;Effects of ARHI on breast cancer cell biological behavior regulated by microRNA 221; The downregulation of ARHI was regulated by miR-221 in prostate cancer cell lines; However it has not been reported whether ARHI is regulated by miR-221 in breast cancer; To address whether ARHI is regulated by miR-221 in breast cancer cell lines the results in this study showed that a significant inverse correlation existed between ARHI and miR-221; The inhibition of miR-221 induced a significant upregulation of ARHI in MCF-7 cells; To prove a direct interaction between miR-221 and ARHI mRNA ARHI 3'UTR which includes the potential target site for miR-221 was cloned downstream of the luciferase reporter gene of the pMIR-REPORT vector to generate the pMIR-ARHI-3'UTR vector; The results confirmed a direct interaction of miR-221 with a target site on the 3'UTR of ARHI; This study demonstrated for the first time that the downregulation of ARHI in breast cancer cells could be regulated by miR-221;MicroRNA 221 and 222 have been shown to regulate ARHI expression negatively; Expression of ARHI and microRNA 221 and 222 was measured by real-time reverse transcription-polymerase chain reaction; Whether ARHI and microRNA 221 and 222 could be considered as biomarkers for disease progression in prostate cancer requires further investigation
117 hsa-miR-21-5p DLG1 1.51 0 -0.14 0.08412 miRNAWalker2 validate -0.19 0 NA
118 hsa-miR-21-5p DMD 1.51 0 -1.66 0 miRNAWalker2 validate -0.77 0 NA
119 hsa-miR-21-5p DOCK4 1.51 0 -0.2 0.07305 miRNAWalker2 validate; miRTarBase -0.11 0.00485 NA
120 hsa-miR-21-5p DOCK5 1.51 0 -0.64 0.00098 miRNAWalker2 validate; miRTarBase -0.25 0.00043 NA
121 hsa-miR-21-5p DOK6 1.51 0 -1.91 0 mirMAP -0.47 8.0E-5 NA
122 hsa-miR-221-3p DPP8 1.12 0 -0.27 0.06918 MirTarget -0.1 0.02426 NA
123 hsa-miR-21-3p DSG1 -0.48 0.003 -2.56 0 MirTarget -0.64 0 NA
124 hsa-miR-21-5p DST 1.51 0 -0.38 0.00155 mirMAP -0.19 1.0E-5 22403704 While the EDCs and estrogen similarly altered the expression of multiple microRNAs in MCF-7 cells including miR-21 differential patterns of microRNA expression were induced by DDT and BPA compared to estrogen
125 hsa-miR-21-5p DUSP10 1.51 0 -1.25 0 miRNAWalker2 validate; miRTarBase -0.34 0 NA
126 hsa-miR-21-3p DYNC1I1 -0.48 0.003 1.67 1.0E-5 MirTarget -0.34 0.00383 NA
127 hsa-miR-21-3p EBF3 -0.48 0.003 1.74 0 mirMAP -0.43 0 NA
128 hsa-miR-21-5p EGFR 1.51 0 -1.02 0 miRNAWalker2 validate; miRTarBase -0.44 0 24198203; 20113523; 24012640; 24331411; 26563758; 19597153; 26026961; 20048743 In radically resected NSCLC patients the expression levels of miR-21 10b in patients with EGFR mutation were much higher than those without mutation;Thus the miR-21 inhibitor might interrupt the activity of EGFR pathways independently of PTEN status;Further the expression of miR-21 is regulated by EGFR via the activation of β-catenin and AP-1; These data indicate that a feedback loop exists between miR-21 and EGFR; These results clarify a novel association between miR-21 and EGFR in the regulation of cancer cell progression;MiR 21 overexpression is associated with acquired resistance of EGFR TKI in non small cell lung cancer;Higher expression levels of miR-21 AmiR-27a and miR-218 detected in this study suggest potential roles of these miRNAs in primary resistance to EGFR-TKI in advanced NSCLC patients with EGFR exon 19 deletion mutations;MiR 21 is an EGFR regulated anti apoptotic factor in lung cancer in never smokers; The changes in expression of some of these miRNAs including miR-21 were more remarkable in cases with EGFR mutations than in those without these mutations; In the never-smoker-derived lung adenocarcinoma cell line H3255 with mutant EGFR and high levels of p-EGFR and miR-21 antisense inhibition of miR-21 enhanced AG1478-induced apoptosis; In a never-smoker-derived adenocarcinoma cell line H441 with wild-type EGFR the antisense miR-21 not only showed the additive effect with AG1478 but also induced apoptosis by itself; These results suggest that aberrantly increased expression of miR-21 which is enhanced further by the activated EGFR signaling pathway plays a significant role in lung carcinogenesis in never-smokers as well as in smokers and is a potential therapeutic target in both EGFR-mutant and wild-type cases;Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR mutated lung cancer via nickel induced microRNA 21 expression;Downregulation of miR 21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status
129 hsa-miR-21-5p EIF1AX 1.51 0 -0.29 0.00114 miRNATAP -0.23 0 NA
130 hsa-miR-221-3p EIF4E3 1.12 0 -1.66 0 miRNATAP -0.36 0 NA
131 hsa-miR-21-5p EIF4EBP2 1.51 0 -0.11 0.27493 miRNAWalker2 validate -0.25 0 NA
132 hsa-miR-21-5p EIF5 1.51 0 -0.72 0 miRNAWalker2 validate -0.26 0 NA
133 hsa-miR-21-5p ELF2 1.51 0 -0.39 0 MirTarget; miRNATAP -0.17 0 NA
134 hsa-miR-21-3p ELK4 -0.48 0.003 0.24 0.02672 mirMAP -0.11 0.0007 NA
135 hsa-miR-21-5p ENTPD4 1.51 0 -0.41 0.00079 mirMAP -0.14 0.00192 NA
136 hsa-miR-21-5p EPM2A 1.51 0 -1.16 0 miRNAWalker2 validate -0.56 0 NA
137 hsa-miR-21-3p EPM2AIP1 -0.48 0.003 -0.3 0.00244 MirTarget -0.15 0 NA
138 hsa-miR-21-5p EPM2AIP1 1.51 0 -0.3 0.00244 mirMAP -0.28 0 NA
139 hsa-miR-221-3p ERCC4 1.12 0 -0.4 0.00032 MirTarget -0.24 0 NA
140 hsa-miR-21-3p ESR1 -0.48 0.003 -4.12 0 mirMAP -0.31 0.00839 25969534; 19264808; 25337203; 21131358 Dehydroepiandrosterone Activation of G protein coupled Estrogen Receptor Rapidly Stimulates MicroRNA 21 Transcription in Human Hepatocellular Carcinoma Cells;miR-21 is higher in ER alpha positive than negative tumors but no one has examined how estradiol E2 regulates miR-21 in breast cancer cells; The E2-induced reduction in miR-21 was inhibited by 4-hydroxytamoxifen 4-OHT ICI 182 780 Faslodex and siRNA ER alpha indicating that the suppression is ER alpha-mediated; ER alpha and ER beta agonists PPT and DPN inhibited and 4-OHT increased miR-21 expression; These results are the first to demonstrate that E2 represses the expression of an oncogenic miRNA miR-21 by activating estrogen receptor in MCF-7 cells;Odds ratios ORs showed that miR-21 expression was closely associated with estrogen receptor ER progesterone receptor PR lymph node metastasis histological grade Her2/neu;Induction of miR 21 by retinoic acid in estrogen receptor positive breast carcinoma cells: biological correlates and molecular targets
141 hsa-miR-221-3p ESR1 1.12 0 -4.12 0 miRNAWalker2 validate; miRNATAP -1.1 0 25483016 HBx protein induced upregulation of microRNA 221 promotes aberrant proliferation in HBV‑related hepatocellular carcinoma by targeting estrogen receptor α
142 hsa-miR-21-5p ESYT2 1.51 0 -0.17 0.03903 miRNAWalker2 validate; MirTarget -0.12 6.0E-5 NA
143 hsa-miR-221-3p ETS1 1.12 0 -0.89 0 miRTarBase; miRNATAP -0.16 0.00028 21711453 To close the loop we demonstrate ETS-1 as a direct target of miR-222 but not miR-221 showing the novel option of their uncoupled functions
144 hsa-miR-221-3p ETS2 1.12 0 -1.76 0 miRNATAP -0.36 0 NA
145 hsa-miR-21-5p EXOC5 1.51 0 -0.38 0 miRNAWalker2 validate -0.2 0 NA
146 hsa-miR-21-5p FAM107B 1.51 0 -0.78 0 miRNATAP -0.24 0 NA
147 hsa-miR-21-5p FAM126B 1.51 0 -0.64 0 miRNAWalker2 validate -0.28 0 NA
148 hsa-miR-221-3p FAM13A 1.12 0 -2.58 0 miRNATAP -0.57 0 NA
149 hsa-miR-21-5p FAM46A 1.51 0 -1.45 0 miRNAWalker2 validate; miRNATAP -0.31 0 NA
150 hsa-miR-21-5p FAM63B 1.51 0 -0.54 0.00241 miRNATAP -0.21 0.00123 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 92 1784 6.526e-11 3.036e-07
2 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 87 1805 6.518e-09 1.063e-05
3 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 58 1004 6.854e-09 1.063e-05
4 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 23 229 2.831e-08 3.293e-05
5 POSITIVE REGULATION OF GENE EXPRESSION 82 1733 4.349e-08 4.047e-05
6 PROTEIN PHOSPHORYLATION 53 944 8.176e-08 6.34e-05
7 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 78 1656 1.187e-07 6.906e-05
8 REGULATION OF CELLULAR COMPONENT MOVEMENT 46 771 1.098e-07 6.906e-05
9 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 72 1517 2.937e-07 0.0001519
10 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 66 1360 4.479e-07 0.0002019
11 NEGATIVE REGULATION OF CELL COMMUNICATION 60 1192 4.773e-07 0.0002019
12 INTRACELLULAR SIGNAL TRANSDUCTION 73 1572 5.517e-07 0.000212
13 PHOSPHORYLATION 61 1228 5.923e-07 0.000212
14 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 76 1672 7.148e-07 0.0002376
15 REGULATION OF CELL DIFFERENTIATION 69 1492 1.362e-06 0.0004226
16 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 44 801 1.953e-06 0.0005679
17 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 52 1021 2.096e-06 0.0005738
18 TISSUE DEVELOPMENT 69 1518 2.496e-06 0.0006451
19 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 84 1977 2.665e-06 0.0006526
20 NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 14 121 2.811e-06 0.000654
21 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 39 689 3.772e-06 0.0008358
22 NEGATIVE REGULATION OF GENE EXPRESSION 67 1493 5.451e-06 0.001103
23 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 67 1492 5.332e-06 0.001103
24 REGULATION OF TRANSFERASE ACTIVITY 48 946 5.848e-06 0.001134
25 REGULATION OF DEVELOPMENTAL GROWTH 22 289 6.269e-06 0.001145
26 RESPONSE TO OXYGEN CONTAINING COMPOUND 63 1381 6.396e-06 0.001145
27 REGULATION OF CELL DEATH 66 1472 6.644e-06 0.001145
28 RESPONSE TO ENDOGENOUS STIMULUS 65 1450 7.918e-06 0.001281
29 SERTOLI CELL DIFFERENTIATION 6 20 7.982e-06 0.001281
30 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 42 799 9.904e-06 0.001487
31 NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 28 437 9.853e-06 0.001487
32 REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 21 278 1.142e-05 0.00161
33 REGULATION OF PROTEIN MODIFICATION PROCESS 73 1710 1.135e-05 0.00161
34 POSITIVE REGULATION OF LOCOMOTION 27 420 1.337e-05 0.001821
35 APOPTOTIC MITOCHONDRIAL CHANGES 9 57 1.37e-05 0.001821
36 REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY INVOLVED IN APOPTOTIC PROCESS 6 22 1.471e-05 0.001901
37 POSITIVE REGULATION OF MOLECULAR FUNCTION 75 1791 1.649e-05 0.002074
38 ENSHEATHMENT OF NEURONS 11 91 2.149e-05 0.002498
39 AXON ENSHEATHMENT 11 91 2.149e-05 0.002498
40 RESPONSE TO ABIOTIC STIMULUS 49 1024 2.202e-05 0.002498
41 REGULATION OF CELL PROLIFERATION 65 1496 2.118e-05 0.002498
42 CELLULAR RESPONSE TO HYDROGEN PEROXIDE 9 61 2.41e-05 0.002643
43 RESPONSE TO ALCOHOL 24 362 2.443e-05 0.002643
44 REGULATION OF KINASE ACTIVITY 40 776 2.527e-05 0.002672
45 SERTOLI CELL DEVELOPMENT 5 15 2.667e-05 0.002758
46 POSITIVE REGULATION OF CATABOLIC PROCESS 25 395 3.593e-05 0.003483
47 CARDIOVASCULAR SYSTEM DEVELOPMENT 40 788 3.562e-05 0.003483
48 CIRCULATORY SYSTEM DEVELOPMENT 40 788 3.562e-05 0.003483
49 NEGATIVE REGULATION OF PHOSPHORYLATION 26 422 3.967e-05 0.003767
50 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 38 740 4.377e-05 0.004073
51 NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 9 66 4.592e-05 0.004102
52 REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 11 99 4.761e-05 0.004102
53 REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS 11 99 4.761e-05 0.004102
54 NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY 9 66 4.592e-05 0.004102
55 NEGATIVE REGULATION OF DEVELOPMENTAL GROWTH 10 84 5.788e-05 0.004897
56 NEGATIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 7 40 6.351e-05 0.005144
57 PALATE DEVELOPMENT 10 85 6.411e-05 0.005144
58 NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 11 102 6.279e-05 0.005144
59 ORGAN MORPHOGENESIS 41 841 7.009e-05 0.005346
60 NEUROGENESIS 60 1402 6.93e-05 0.005346
61 REGULATION OF PHOSPHORUS METABOLIC PROCESS 67 1618 6.902e-05 0.005346
62 POSITIVE REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY 5 18 7.139e-05 0.005358
63 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 51 1135 7.605e-05 0.005444
64 BEHAVIOR 29 516 7.585e-05 0.005444
65 CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES 11 104 7.508e-05 0.005444
66 REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 23 365 7.818e-05 0.005512
67 POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS 20 296 8.846e-05 0.006143
68 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 27 470 9.293e-05 0.006359
69 ANDROGEN METABOLIC PROCESS 6 30 9.828e-05 0.006628
70 REGULATION OF ORGAN GROWTH 9 73 0.0001027 0.00683
71 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 59 1395 0.0001103 0.007228
72 RESPONSE TO MECHANICAL STIMULUS 16 210 0.0001122 0.007253
73 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 46 1008 0.0001214 0.007735
74 RESPONSE TO INORGANIC SUBSTANCE 27 479 0.000127 0.007987
75 TISSUE MORPHOGENESIS 29 533 0.0001329 0.008247
76 NEGATIVE REGULATION OF CELL PROLIFERATION 33 643 0.0001405 0.008603
77 PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 41 873 0.0001566 0.009223
78 NEGATIVE REGULATION OF CELL DEATH 41 872 0.0001528 0.009223
79 REGULATION OF BMP SIGNALING PATHWAY 9 77 0.0001559 0.009223
80 NEGATIVE REGULATION OF ORGAN GROWTH 5 21 0.0001591 0.009253
NumGOOverlapSizeP ValueAdj. P Value
1 ENZYME BINDING 83 1737 2.292e-08 1.065e-05
2 PROTEIN SERINE THREONINE KINASE ACTIVITY 34 445 1.73e-08 1.065e-05
3 PROTEIN KINASE ACTIVITY 41 640 8.441e-08 1.648e-05
4 KINASE ACTIVITY 49 842 8.869e-08 1.648e-05
5 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 55 992 6.925e-08 1.648e-05
6 SMAD BINDING 12 72 2.764e-07 4.28e-05
7 TRANSLATION REPRESSOR ACTIVITY 7 20 4.122e-07 5.471e-05
8 NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY 59 1199 1.25e-06 0.0001452
9 RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING 36 629 7.035e-06 0.0007261
10 UBIQUITIN LIKE PROTEIN TRANSFERASE ACTIVITY 27 420 1.337e-05 0.001242
11 TRANSLATION REGULATOR ACTIVITY 7 35 2.56e-05 0.002162
12 TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 22 328 4.446e-05 0.003442
13 GROWTH FACTOR BINDING 12 123 7.919e-05 0.005659
14 KINASE BINDING 32 606 0.0001054 0.006527
15 PDZ DOMAIN BINDING 10 90 0.0001045 0.006527
16 RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY 10 92 0.0001259 0.00731
17 RECEPTOR SIGNALING PROTEIN ACTIVITY 14 172 0.000149 0.008144
18 REGULATORY REGION NUCLEIC ACID BINDING 39 818 0.0001669 0.008612
NumGOOverlapSizeP ValueAdj. P Value
1 TRANSFERASE COMPLEX 43 703 1.472e-07 8.598e-05
2 UBIQUITIN LIGASE COMPLEX 22 262 1.262e-06 0.0002418
3 PML BODY 13 97 1.193e-06 0.0002418
4 CULLIN RING UBIQUITIN LIGASE COMPLEX 16 150 1.656e-06 0.0002418
5 CATALYTIC COMPLEX 49 1038 3.116e-05 0.003439
6 CUL3 RING UBIQUITIN LIGASE COMPLEX 9 64 3.575e-05 0.003439
7 CELL LEADING EDGE 23 350 4.122e-05 0.003439
8 NEURON PART 55 1265 9.414e-05 0.006873
9 AXONAL GROWTH CONE 5 20 0.0001238 0.008034
10 PLASMA MEMBRANE REGION 43 929 0.000149 0.008702
11 SOMATODENDRITIC COMPARTMENT 33 650 0.0001716 0.009108

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 FoxO_signaling_pathway_hsa04068 16 132 2.91e-07 1.513e-05
2 MAPK_signaling_pathway_hsa04010 21 295 2.778e-05 0.0007222
3 ErbB_signaling_pathway_hsa04012 10 85 6.411e-05 0.001111
4 Cellular_senescence_hsa04218 13 160 0.000259 0.003367
5 Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 11 139 0.0009421 0.008126
6 cGMP_PKG_signaling_pathway_hsa04022 12 163 0.001062 0.008126
7 HIF_1_signaling_pathway_hsa04066 9 100 0.001094 0.008126
8 Ras_signaling_pathway_hsa04014 14 232 0.002822 0.01834
9 mTOR_signaling_pathway_hsa04150 10 151 0.005737 0.03186
10 Hippo_signaling_pathway_hsa04390 10 154 0.006568 0.03186
11 TNF_signaling_pathway_hsa04668 8 108 0.00674 0.03186
12 Wnt_signaling_pathway_hsa04310 9 146 0.01329 0.05759
13 Rap1_signaling_pathway_hsa04015 11 206 0.01787 0.07147
14 PI3K_Akt_signaling_pathway_hsa04151 16 352 0.02042 0.07585
15 Jak_STAT_signaling_pathway_hsa04630 9 162 0.0244 0.07905
16 Mitophagy_animal_hsa04137 5 65 0.02572 0.07905
17 Gap_junction_hsa04540 6 88 0.02584 0.07905
18 cAMP_signaling_pathway_hsa04024 10 198 0.03247 0.0896
19 Sphingolipid_signaling_pathway_hsa04071 7 118 0.03274 0.0896
20 Adherens_junction_hsa04520 5 72 0.03773 0.0981
21 Phosphatidylinositol_signaling_system_hsa04070 6 99 0.04241 0.1018
22 Regulation_of_actin_cytoskeleton_hsa04810 10 208 0.04307 0.1018
23 Autophagy_animal_hsa04140 7 128 0.04741 0.1072
24 Peroxisome_hsa04146 5 83 0.06258 0.1356
25 Tight_junction_hsa04530 8 170 0.07272 0.1513
26 Phospholipase_D_signaling_pathway_hsa04072 7 146 0.08307 0.1661
27 Cytokine_cytokine_receptor_interaction_hsa04060 11 270 0.09006 0.1734
28 p53_signaling_pathway_hsa04115 4 68 0.09756 0.1812
29 ABC_transporters_hsa02010 3 45 0.1087 0.1949
30 Hedgehog_signaling_pathway_hsa04340 3 47 0.1197 0.2076
31 Necroptosis_hsa04217 7 164 0.1307 0.2192
32 Focal_adhesion_hsa04510 8 199 0.1418 0.2223
33 Apelin_signaling_pathway_hsa04371 6 137 0.1419 0.2223
34 Apoptosis_hsa04210 6 138 0.1453 0.2223
35 TGF_beta_signaling_pathway_hsa04350 4 84 0.1701 0.2527
36 VEGF_signaling_pathway_hsa04370 3 59 0.1934 0.2794
37 AMPK_signaling_pathway_hsa04152 5 121 0.201 0.2824
38 Cell_cycle_hsa04110 5 124 0.2147 0.2938
39 Calcium_signaling_pathway_hsa04020 6 182 0.3266 0.4355
40 Phagosome_hsa04145 5 152 0.3525 0.4583
41 Oocyte_meiosis_hsa04114 4 124 0.3952 0.5012
42 Endocytosis_hsa04144 7 244 0.4379 0.5422
43 Lysosome_hsa04142 3 123 0.6159 0.7083
44 ECM_receptor_interaction_hsa04512 2 82 0.6266 0.7083
45 NF_kappa_B_signaling_pathway_hsa04064 2 95 0.7052 0.764
46 Cell_adhesion_molecules_.CAMs._hsa04514 3 145 0.7238 0.7681

Quest ID: 4934a1e23eb39bde6d4d616b0aa0b389